Trevi Therapeutics (TRVI) Change in Accured Expenses (2018 - 2026)

Trevi Therapeutics' Change in Accured Expenses history runs 9 years deep, the most recent figure standing at -$1.1 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 28.38% year-over-year to -$1.1 million in Q1 2026; TTM through Mar 2026 was -$989000.0, a 149.4% decrease from a year earlier, with the FY2025 full-year figure at -$1.4 million, down 155.21% from the prior year.
• Change in Accured Expenses declined to -$1.1 million in Q1 2026 per TRVI's latest filing, from -$555000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.2 million in Q3 2024 and bottomed at -$1.5 million in Q1 2025.
• The 5-year median for Change in Accured Expenses is $14000.0 (2022), against an average of -$30235.3.
• Biggest YoY gain for Change in Accured Expenses was 375.27% in 2024; the steepest drop was 3070.83% in 2024.
• Year by year, Change in Accured Expenses stood at -$1.3 million in 2022, then soared by 101.85% to $24000.0 in 2023, then slumped by 3070.83% to -$713000.0 in 2024, then climbed by 22.16% to -$555000.0 in 2025, then slumped by 93.69% to -$1.1 million in 2026.
• Per Business Quant, the three latest TRVI Change in Accured Expenses figures stand at -$1.1 million (Q1 2026), -$555000.0 (Q4 2025), and $143000.0 (Q3 2025).